Business
FDA Rejects Promising Cancer Drug Developed in China
The Brief
- The FDA declined to approve an investigational PD-1/VEGF bispecific antibody for an indication in non-small cell lung cancer (NSCLC), according to drugmaker Summit Therapeutics.
- The drug was developed in China and is described by MedPage Today as closely watched.
- The source says the drug could soon advance, but the available text does not give details on next steps.
Why it matters
Regulatory decisions determine which experimental cancer therapies reach patients, and this rejection of a closely watched bispecific antibody shows how such candidates face scrutiny when they are developed abroad.
Who’s affected
- patients with non-small cell lung cancer
- oncologists and clinical researchers
- drug developers following FDA decisions
- #fda
- #lung cancer
- #nsclc
- #pd-1
- #vegf
- #bispecific antibody
(MedPage Today) -- The FDA declined to approve a closely watched drug developed in China for an indication in non-small cell lung cancer (NSCLC), drugmaker Summit Therapeutics announced, though the investigational bispecific antibody could soon...